Rilpivirine, sold under the brand name Edurant among others, is a medication developed by Tibotec for the treatment of HIV/AIDS. It is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that prevents HIV from replicating by inhibiting the reverse transcriptase enzyme. Rilpivirine is usually taken once daily in combination with other antiretroviral medications as part of a highly active antiretroviral therapy (HAART) regimen.
Parent: Rilpivirine
Parent: Rilpivirine
Parent: Rilpivirine
Parent: Rilpivirine
Parent: Rilpivirine
Parent: Rilpivirine
Parent: Rilpivirine
Impurities in Rilpivirine can arise due to synthesis processes, degradation, or storage conditions. Regulatory authorities like the FDA, ICH, and EMA enforce strict impurity limits to ensure the drug’s safety and efficacy.
Process-Related Impurities
Degradation Impurities
Elemental Impurities
Analytical Techniques for Impurity Detection
Rilpivirine belongs to the class of non-nucleoside reverse transcriptase inhibitors (NNRTIs). It works by inhibiting the reverse transcriptase enzyme, which is essential for HIV replication.
Rilpivirine binds to reverse transcriptase and causes a conformational change that inhibits the enzyme’s activity. This prevents the conversion of viral RNA into DNA, thereby stopping HIV replication.
Omeprazole, a proton pump inhibitor (PPI), increases stomach pH, which can significantly reduce the absorption and effectiveness of rilpivirine. Therefore, co-administration is contraindicated.
Common side effects of rilpivirine include headache, depression, insomnia, nausea, and rash. Serious side effects can involve liver problems, severe skin reactions, and mood changes.
